Frexalt

About

The development of disease modifying therapies for relapsing forms of multiple sclerosis (MS) has led to significant decrease of morbidity for people with MS. For individuals with relapsing-remitting MS, disability worsening starts from disease onset, and more than 50% of patients evolve to secondary progressive disease within 15 to 20 years after diagnosis.

The goal of this study is to assess the efficacy of frexalimab compared to the standard of care in relapsing MS, teriflunomide, in reducing annualized relapse rate and slowing disability worsening, and to assess its safety and tolerability in adult participants with relapsing forms of MS.